Oxular Limited Announces Acceptance of IND for Suprachoroidal OXU-001 for the Treatment of Diabetic Macular Edema
Oxular Limited, a clinical-stage ophthalmic company developing long-lasting targeted treatments for retinal disorders to improve patients’ vision, today announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug Application (IND) for suprachoroidal OXU-001 for the treatment of diabetic macular edema (DME). The IND enables advancement of the OXEYE Phase 2 trial, which will evaluate the safety and efficacy of OXU-001 and the potential to provide retinal specialists with a potent, long-lasting, safe, and broad-acting anti-edema and anti-inflammatory treatment for high-prevalence retinal disorders, beginning with DME.
OXU-001 is dexamethasone formulated in a novel biodegradable drug preparation known as Oxuspheres®. OXU-001 will be delivered to the posterior suprachoroidal space of the eye via Oxulumis®, Oxular’s proprietary illuminated microcatheter. This in-office treatment could lead to enhanced efficacy, favorable tolerability, and extended durability to address key unmet needs for people with DME and other retinal disorders.
In 12-month preclinical studies, OXU-001 was well-tolerated and related pharmacokinetic data confirmed that therapeutic drug levels were consistently maintained in target retinal tissues. These data suggest that a single treatment of OXU-001 may provide up to twelve-month treatment effects with an improved clinical safety profile.
“The IND clearance for OXU-001 marks a significant milestone for Oxular,” said Thomas Cavanagh, Chief Executive Officer of Oxular. “DME is the most common and sight-threatening complication of diabetic eye disease and can be debilitating for patients who are often of working age. Today’s treatment approaches have limited durability, requiring frequent anti-VEGF injections into the eye. Also, typically more than two OZURDEX® implants per year may be required. The opportunity to provide patients with a targeted, in-office treatment just once a year could be a game-changer for this prevalent disease. We look forward to advancing OXU-001 into the clinic and evaluating its therapeutic impact in 2023.”
About Oxular
Oxular is a biotechnology company developing long-lasting retinal treatments, delivered suprachoroidally, to improve patients’ vision so they can live better lives. The company has engineered sustained-release drug formulations designed to last up to one year following single dosing and delivery technology to access tissues in the posterior suprachoroidal space via routine, in-office administration. This unique combination aims to substantially improve patients’ vision by increasing therapeutic effectiveness, while reducing side-effects and minimizing the frequency of treatments. Oxular is developing a deep portfolio of product candidates that includes treatments for prevalent retinal diseases, such as diabetic macular edema and diabetic retinopathy. For more information, please visit Oxular.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005116/en/
Contact information
Monique Allaire
THRUST Strategic Communications
monique@thrustsc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
10-Year Partnership Between ISN ® and Yara International Enhances Ongoing Commitment to Contractor Safety14.5.2025 11:00:00 EEST | Press release
ISN, the global leader in contractor and supplier information management services, celebrates 10 years of partnership with the European division of Yara International (Yara), a leading provider of crop nutrition and sustainable agricultural solutions. After a successful implementation in the Americas, Yara adopted ISNetworld across its European sites in 2015, expanding its use of the contractor management platform, streamlining processes, and improving operational efficiency. “Over the past decade, ISN has been instrumental to Yara’s contractor management processes in Norway and the Netherlands," said Steinar Bjelland, Procurement Manager at Yara. "Leveraging ISNetworld tools and services such as RAVS 360™ and acknowledgment form tracking, along with ISN’s multilingual support, has helped Yara optimise compliance, improve communication, and effectively align our protocols with industry best practices.” Headquartered in Oslo, Norway, Yara operates in more than 60 countries. Yara works t
Ares Management Opens Milan Office14.5.2025 11:00:00 EEST | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the opening of a new office in Milan, the firm’s latest office in Europe. The office will enhance Ares’ access to the Italian market, and its ability to raise and invest capital across its strategies, particularly within its European Direct Lending business, as well as the Wealth Management and European Real Estate platforms. This latest opening underscores Ares’ commitment to a highly localized approach to investing in Europe, which the firm entered in 2007 through the opening of a London office, followed by Paris, Frankfurt and Stockholm in 2009 and, most recently, Amsterdam and Madrid in 2019. Across its investment strategies, including European Direct Lending and European Real Estate, Ares has deployed over €1.6 billion to support Italian businesses and assets, as of March 31, 2025, and Ares expects to accelerate this activity in the coming years. Tyrone Cooney, Partn
Intelsat, Cubic³ Complete Vehicle Satellite Connectivity Test, Advancing Ubiquitous Connectivity Vision14.5.2025 10:00:00 EEST | Press release
Intelsat and Cubic³ have successfully completed a critical vehicle satellite connectivity test, marking a significant milestone in their joint mission to create a seamless connectivity service for all types of vehicles. The test demonstrated successful integration between Intelsat satellites and Cubic³’s software platform, showcasing how terrestrial and non-terrestrial networks can seamlessly link to deliver always-on connectivity regardless of location. “Our Memorandum of Understanding and successful test brings us closer to our vision of truly ubiquitous connectivity,” said Bruno Fromont, Intelsat Chief Technology Officer. “By combining Intelsat’s satellite expertise with Cubic³’s innovative connectivity platform, we’re creating solutions that will keep vehicles connected anywhere in the world, enabling critical functions from broadband connectivity, diagnostics to eventually supporting autonomous driving capabilities.” The successful test focused on a commercial land mobile use case
Norli Liv & Pension Modernizes Investment Operations with Clearwater Analytics14.5.2025 10:00:00 EEST | Press release
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced that Danish pension provider, Norli Liv & Pension, part of the Norli group, has partnered with Clearwater to modernize its investment accounting, reporting and compliance operations. Clearwater will provide Norli with a single, consolidated view of all in-house and outsourced chief investment officer (OCIO) managed holdings across its public and private asset classes—enhancing investment transparency and empowering better, faster decision-making. The platform will also support regulatory compliance through automated workflows and robust, audit-ready reporting. By moving to Clearwater’s single instance, multi-tenant platform, Norli Liv & Pension will eliminate multiple legacy platforms, reduce manual work and accelerate its monthly close. The platform’s “single pane of glass” view will provide users across departments with unified access to accurate, timely data and a
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)14.5.2025 09:14:00 EEST | Press release
GSK plc (LSE/NYSE: GSK) and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, today announced that they have entered into an agreement under which GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD). Under the agreement, GSK will pay $1.2 billion upfront, with potential for additional success-based milestone payments totalling $800 million. Efimosfermin is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), including cirrhosis, and future development in alcohol-related liver disease (ALD), both forms of SLD. Given efimosfermin’s direct antifibrotic mechanism of action and GSK’s dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom